Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RADX | 6-K | mixed | 6/10 | Radiopharm Theranostics reported positive Phase 2b results for imaging agent RAD 101 (93% primary endpoint concordance) | Jul 31, 2026 |
| VRAX | 6-K | bearish | 7/10 | Virax Biolabs is seeking shareholder approval to increase authorized share capital from 2 million to 500 million ordinar | Jul 31, 2026 |
| MBRX | 8-K | bullish | 6/10 | Moleculin reported updated preliminary blinded results from Part A of its pivotal MIRACLE trial for Annamycin in R/R AML | Jul 31, 2026 |
| ELUT | PRESS-RELEASE | neutral | 1/10 | Elutia Inc. announced it will report its Q2 2026 results on August 13, 2026. | Jul 31, 2026 |
| INO | 8-K | bearish | 6/10 | Inovio Pharmaceuticals priced a $20M public offering of 21M shares and warrants for 42M shares (or pre-funded warrants) | Jul 31, 2026 |
| RADX | PRESS-RELEASE | mixed | 6/10 | Radiopharm Theranostics reported positive Phase 2b results for RAD 101 (93% primary endpoint achievement) and plans a Ph | Jul 31, 2026 |
| HOWL | PRESS-RELEASE | mixed | 5/10 | Werewolf Therapeutics reported Q2 2026 net income of $3.7M ($0.08 EPS), a significant swing from a net loss of $18.0M in | Jul 31, 2026 |
| TENX | PRESS-RELEASE | neutral | 5/10 | Tenax Therapeutics reported Q2 2026 net loss of $17.8M ($0.35/share), slightly beating consensus of -$0.36. Cash positio | Jul 31, 2026 |
| LYB | 8-K | bullish | 6/10 | LyondellBasell reported Q2 2026 EPS excluding identified items of $4.30, a 25.6% beat vs consensus of $3.42, driven by s | Jul 31, 2026 |
| MRNA | 8-K | mixed | 6/10 | Moderna reported Q2 2026 revenue of $145M (vs $103.9M consensus) and GAAP EPS of -$1.97 (vs -$2.06 consensus), a modest | Jul 31, 2026 |
| HOWL | 8-K | mixed | 5/10 | Werewolf Therapeutics reported Q2 2026 net income of $3.7M ($0.08 EPS), a significant swing from a net loss of $18.0M in | Jul 31, 2026 |
| TENX | 8-K | neutral | 5/10 | Tenax Therapeutics reported Q2 2026 results with a net loss of $17.8M ($0.35/share), slightly beating consensus of -$0.3 | Jul 31, 2026 |
| ABBV | 8-K | bullish | 7/10 | AbbVie reported Q2 2026 adjusted EPS of $3.65, a 1.2% beat vs. consensus of $3.61, on revenue of $16.99B (above $16.76B | Jul 31, 2026 |
| JSPR | 8-K | neutral | 3/10 | Jasper Therapeutics filed an 8-K confirming the record date (July 16, 2026) for contingent value rights (CVRs) issued to | Jul 31, 2026 |
| ISPC | EFFECT | bearish | 7/10 | iSpecimen's S-1 registration statement (File No. 333-297001) became effective on July 30, 2026, enabling the company to | Jul 31, 2026 |
| HYFT | EFFECT | neutral | 2/10 | MindWalk Holdings Corp. (HYFT) received SEC effectiveness for its shelf registration statement (File No. 333-297424) on | Jul 31, 2026 |
| GLSI | INSIDER-BUY | bullish | 4/10 | Greenwich LifeSciences CEO/CFO Snehal Patel purchased $88K of GLSI shares on the open market over four days (July 23-28, | Jul 31, 2026 |
| ABT | INST-CLUSTER | mixed | 4/10 | A mixed institutional cluster in ABT for Q2 2026 shows four asset managers adding $103.5M in net new holdings (led by Da | Jul 31, 2026 |
| CYTK | CLUSTER | neutral | 2/10 | CEO Robert Blum and EVP/Chief Commercial Officer Andrew Callos sold a combined $1.72M in open-market shares over a 4-day | Jul 31, 2026 |
| MPLT | 144 | bearish | 5/10 | Novo Holdings A/S, a major affiliate shareholder of MapLight Therapeutics, has filed a Form 144 to sell up to 1,600,000 | Jul 30, 2026 |
| PRTA | CLUSTER | neutral | 2/10 | Two C-suite insiders at Prothena (PRTA) sold a combined $136K in open-market sales on July 29, 2026, following tax-withh | Jul 30, 2026 |
| VREOF | 8-K | neutral | 5/10 | Vireo Growth Inc. (VREOF) entered into a definitive merger agreement to acquire Planet 13 Holdings Inc. in an all-stock | Jul 30, 2026 |
| TLX | PRESS-RELEASE | neutral | 1/10 | Telix Pharmaceuticals Limited announced it will host a conference call on August 20, 2026 to discuss its half-year 2026 | Jul 30, 2026 |
| CMND | 6-K | bullish | 5/10 | Clearmind Medicine announced positive safety results from Part A of its Phase I/II trial for CMND-100, a non-hallucinoge | Jul 30, 2026 |
| KROS | 8-K | bullish | 6/10 | Keros Therapeutics announced a $20 million development milestone payment from partner Takeda triggered by dosing the fir | Jul 30, 2026 |
| CRIS | 8-K | bullish | 6/10 | Curis Inc. received Nasdaq notice confirming it has regained compliance with the Bid Price Rule (Rule 5550(a)(2)) and is | Jul 30, 2026 |
| MBRX | S-1/A | bearish | 6/10 | Moleculin Biotech filed Amendment No. 1 to its S-1 for a best-efforts offering of up to 4.57M shares (plus pre-funded wa | Jul 30, 2026 |
| ALDX | 8-K | neutral | 2/10 | ALDX executed a 3-year commercial lease for ~4,067 sq ft of office space in Concord, MA to serve as its new corporate he | Jul 30, 2026 |
| TRDA | 144 | bearish | 5/10 | 5AM Ventures V, L.P., an early venture investor and affiliated stockholder of Entrada Therapeutics, filed a Form 144 not | Jul 30, 2026 |
| NRIX | CLUSTER | neutral | 2/10 | Three C-suite insiders at Nurix Therapeutics (CFO, CSO, CLO) exercised stock options and immediately sold a combined ~$2 | Jul 30, 2026 |